The positive modulation of the lysosomal CatB enzyme led to a wide range of influences in the different animal models tested, including reduced amyloidogenic peptide species and protection against early α-synucleinopathy, as well as synaptic and functional improvements in models of age-related cognitive impairment. This evidence concerns the gene TYRP1 and synucleinopathy.